In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody(克隆 10B4 / 10F.9G2) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 CD370(别名 C-type lectin family member 9A 等),适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody(克隆 10B4 / 10F.9G2) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 CD370(别名 C-type lectin family member 9A 等),适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
513801 | 1 mg | ¥11,865
513802 | 5 mg | ¥40,341
513803 | 25 mg | ¥121,023
Product Details
Product Description|In Vivo Grade Recombinant Anti-mouse CD370 / PD-L1 Bispecific Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone 10B4 / 10F.9G2
Background Information
CD370, also known as CLEC9A (C-type lectin domain family 9 member A), is a receptor primarily expressed on a specialized subset of dendritic cells known as CD141⁺ (BDCA3⁺) dendritic cells in humans. These cells play an essential role in the cross-presentation of antigens, a process by which exogenous antigens are presented on MHC class I molecules to activate cytotoxic CD8⁺ T cells. Structurally, CD370 is a type II transmembrane glycoprotein with a single extracellular C-type lectin-like domain and a short cytoplasmic tail containing an immunoreceptor tyrosine-based activation motif (ITAM-like) that transmits activation signals through the SYK kinase pathway. Functionally, it recognizes exposed actin filaments from necrotic or damaged cells, enabling dendritic cells to uptake and process antigens from dying cells, initiating robust T cell–mediated immune responses.
PD-L1 (Programmed Death-Ligand 1, also known as CD274) is an immune checkpoint molecule expressed on various immune and tumor cells. It interacts with its receptor PD-1 on T cells to inhibit T cell activation, proliferation, and cytokine production, thereby maintaining immune tolerance and preventing autoimmunity. However, many tumors exploit this pathway by overexpressing PD-L1 to suppress anti-tumor immunity and evade immune destruction. Hence, the PD-1/PD-L1 axis has become a central target in cancer immunotherapy, with monoclonal antibodies like pembrolizumab and atezolizumab already benefiting patients across multiple cancer types.
Combining CD370 and PD-L1 in a single bispecific antibody offers a synergistic therapeutic strategy that unites immune activation with checkpoint blockade. A bispecific antibody targeting CD370 could specifically target and deliver immune-stimulating signals or antigen payloads directly to cross-presenting dendritic cells, enhancing their ability to prime CD8⁺ T cells. Simultaneously, engagement of PD-L1 blockade would relieve inhibitory signals in the tumor microenvironment, sustaining this T cell activation. Such a dual-target approach could bridge innate and adaptive immunity, reinvigorating existing T cells while recruiting new ones through enhanced antigen presentation. Additionally, the localized targeting of dendritic cells may reduce systemic immune-related toxicities often seen with global checkpoint inhibition. Overall, a CD370 × PD-L1 bispecific antibody could potentiate anti-tumor immunity by turning immunologically “cold” tumors into “hot” ones, maximizing T cell activation and persistence while minimizing off-target effects, representing a promising direction in next-generation cancer immunotherapies.
Data Sheets
Cat # Size Price Quantity 5138011 mg Add to Cart5138025 mg Add to Cart51380325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody(513801)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd274-pd-l1-bispecific-antibod.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody(513801). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd274-pd-l1-bispecific-antibod.html
@misc{biocsp_item_in_vivo_star_anti_mouse_cd370_cd274_pd_l1_bispecific_antibod,
title = {In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody(513801)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd274-pd-l1-bispecific-antibod.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源